Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Core Points - Oncocyte Corp. will report its fourth quarter 2024 financial results on March 24, 2025, after market close [1] - A live Zoom webinar will be held at 2:00 p.m. PT on the same day to discuss the financial results and include a Q&A session [2] Company Overview - Oncocyte is a leading diagnostics technology company focused on providing clarity and confidence to physicians and patients through its tests [3] - Key products include: - VitaGraft™, a clinical blood-based solid organ transplantation monitoring test - GraftAssure™, a research use only (RUO) blood-based solid organ transplantation monitoring test - DetermaIO™, a gene expression test predicting response to immunotherapies - DetermaCNI™, a blood-based monitoring tool for therapeutic efficacy in cancer patients [3]